N-(2-(3-CYANO-2-AZABICYCLO[3.1.0!HEXAN-2-YL)-2-OXOETHYL)-CHINOLIN-4-CARBOXAMIDE
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- ASTRAZENECA AB
- Filing Date
- 2023-06-20
- Publication Date
- 2026-05-27
AI Technical Summary
There is a need for pharmacologically appropriate FAP inhibitors that can selectively inhibit FAP activity to treat conditions like NASH and other diseases associated with FAP activity, as no approved agents are currently available.
Development of N-(2-(3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)quinoline-4-carboxamides and their pharmaceutically acceptable salts, which act as FAP inhibitors, offering therapeutic potential for conditions such as NASH, type 2 diabetes mellitus, cardiovascular conditions, obesity, obesity-related conditions, fibrosis, keloid disorders, inflammation, and cancer.
The compounds effectively inhibit FAP activity, providing therapeutic benefits for FAP-mediated conditions by addressing multiple mechanisms associated with FAP, including reducing fibrosis and metabolic inactivation of FGF21, thus offering potential treatments for NASH and other diseases.